{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:51:13Z","timestamp":1770072673164,"version":"3.49.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.amjmed.2003.10.022","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T07:10:57Z","timestamp":1082531457000},"page":"76-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S1","title":["Managing the patient with diabetes mellitus and heart failure: issues and considerations"],"prefix":"10.1016","volume":"116","author":[{"given":"Gregg C","family":"Fonarow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2003.10.022_BIB1","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0735-1097(01)01683-7","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult","volume":"38","author":"Hunt","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/hj.1999.v137.95495","article-title":"Hospitalization of patients with heart failure","volume":"137","author":"Haldeman","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB3","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB4","first-page":"S49","article-title":"ADHERE (Acute Decompensated Heart Failure National Registry)","volume":"8","author":"Fonarow","year":"2002","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1067\/mhj.2002.126446","article-title":"The relevance of subgroup-specific treatment effects","volume":"144","author":"Parker","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB7","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/oxfordjournals.eurheartj.a015067","article-title":"Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction","volume":"17","author":"Malmberg","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB9","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/01.CIR.94.9.2285","article-title":"Medical therapy can improve the biological properties of the chronically failing heart","volume":"94","author":"Eichhorn","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0033-0620(98)80030-3","article-title":"Beta-adrenergic blockade in chronic heart failure","volume":"41","author":"Packer","year":"1998","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB11","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI115260","article-title":"Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans","volume":"87","author":"Anderson","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM199602083340607","article-title":"Hypertension and associated metabolic abnormalities\u2014the role of insulin resistance and the sympathoadrenal system","volume":"334","author":"Reaven","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB13","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB14","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-101-3-370","article-title":"The neurohumoral axis in congestive heart failure","volume":"101","author":"Francis","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0002-9149(78)90162-5","article-title":"Plasma norepinephrine in congestive heart failure","volume":"41","author":"Thomas","year":"1978","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB18","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/01.CIR.96.6.1914","article-title":"Beta 2-adrenergic receptor antagonists protect against ventricular fibrillation","volume":"96","author":"Billman","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB19","series-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","article-title":"Renin and angiotensin","author":"Edwin","year":"1996"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0021-9150(87)90264-4","article-title":"Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension","volume":"67","author":"Shieh","year":"1987","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2337\/diacare.14.3.195","article-title":"Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension","volume":"14","author":"Reaven","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diab.23.1.1","article-title":"Plasma norepinephrine and epinephrine in untreated diabetics, during fasting and after insulin administration","volume":"23","author":"Christensen","year":"1974","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0140-6736(68)92163-6","article-title":"Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction","volume":"1","author":"Oliver","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(69)90749-1","article-title":"Increased plasma-free-fatty-acid concentrations and their significance in patients with acute myocardial infarction","volume":"2","author":"Gupta","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(83)90388-4","article-title":"Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction","volume":"2","author":"Tansey","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0002-8703(91)90970-S","article-title":"Pulse rate, coronary heart disease, and death","volume":"121","author":"Gillum","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/oxfordjournals.aje.a113046","article-title":"Heart rate as a prognostic factor for coronary heart disease and mortality","volume":"112","author":"Dyer","year":"1980","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality","volume":"113","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2337\/diacare.23.5.624","article-title":"Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects","volume":"23","author":"Festa","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0002-9149(97)89163-1","article-title":"Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry","volume":"77","author":"Shindler","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB31","doi-asserted-by":"crossref","first-page":"II-58","DOI":"10.1002\/j.1932-8737.1997.tb00014.x","article-title":"Potential role of angiotensin-converting enzyme inhibition in myocardial ischemia and current clinical trials","volume":"20","author":"Pepine","year":"1997","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB32","doi-asserted-by":"crossref","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001\u20132007","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199808203390801","article-title":"Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction","volume":"339","author":"Gottlieb","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-5491.1994.tb02009.x","article-title":"Is there a role for beta-blockers in hypertensive diabetic patients?","volume":"11","author":"Tse","year":"1994","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB35","doi-asserted-by":"crossref","first-page":"1A","DOI":"10.1016\/S0002-9149(99)00358-6","article-title":"Consensus recommendations for the management of chronic heart failure","volume":"83","author":"Packer","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB36","first-page":"357","article-title":"Heart Failure Society of America (HFSA) practice guidelines","volume":"5","year":"1999","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB37","first-page":"145","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published errata appear in N Engl J Med. 2000;342:748 and 2000;342:1376]","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB39","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB40","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of ACE inhibitors and beta blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB41","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB42","unstructured":"V-HeFT positive for enalapril [news]. Br J Hosp Med 1991;45:233"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB43","first-page":"685","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published erratum appears in N Engl J Med 1992;327:1768]","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0002-9149(98)00496-2","article-title":"Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE Trial","volume":"82","author":"O'Connor","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB45","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS [the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study] trial","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB48","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB49","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB50","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB52","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB53","first-page":"II-612","article-title":"Efficacy and safety of initiating carvedilol in patients with severe chronic heart failure","volume":"106","author":"Krum","year":"2002","journal-title":"Circulation"},{"issue":"suppl 3","key":"10.1016\/j.amjmed.2003.10.022_BIB54","first-page":"S2","article-title":"The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes","volume":"3","author":"Fonarow","year":"2002","journal-title":"Rev Cardiovasc Med"},{"issue":"suppl II","key":"10.1016\/j.amjmed.2003.10.022_BIB55","first-page":"II-754","article-title":"Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes?","volume":"104","author":"Mohacsi","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB56","first-page":"I-664","article-title":"Effect of carvedilol on LV function and mortality in diabetic vs non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy [abstract]","volume":"84","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1067\/mhj.2001.117600","article-title":"Challenges of subgroup analyses in multinational clinical trials","volume":"142","author":"Wedel","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1388-9842(01)00174-X","article-title":"Results from post-hoc analyses of the CIBIS II trial","volume":"3","author":"Erdmann","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0002-9149(00)01519-8","article-title":"Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP)","volume":"87","author":"Fonarow","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB60","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0140-6736(02)11601-1","article-title":"Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme)","volume":"360","author":"Cleland","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB61","first-page":"219","article-title":"Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity","volume":"8","author":"Andersson","year":"1994","journal-title":"J Hum Hypertens"},{"issue":"suppl 2","key":"10.1016\/j.amjmed.2003.10.022_BIB62","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1007\/BF01409473","article-title":"Effects of carvedilol on renal function","volume":"38","author":"Dupont","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2003.10.022_BIB63","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/00005344-199219001-00019","article-title":"Effect of long-term carvedilol therapy on renal function in essential hypertension","volume":"19","author":"Tomita","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB64","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","article-title":"Antihypertensive therapy and insulin sensitivity","volume":"11","author":"Jacob","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00004872-199604000-00012","article-title":"Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity","volume":"14","author":"Jacob","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB66","first-page":"551","article-title":"Effect of antihypertensive treatment on qualitative estimates of microalbuminuria","volume":"10","author":"Agrawal","year":"1996","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB67","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1742-1241.1999.tb11793.x","article-title":"Treatment with carvedilol is associated with a significant reduction in microalbuminuria","volume":"53","author":"Fassbinder","year":"1999","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB68","first-page":"212","article-title":"Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria","volume":"12","author":"Marchi","year":"1995","journal-title":"Adv Ther"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB69","doi-asserted-by":"crossref","first-page":"61A","DOI":"10.1016\/0735-1097(93)90465-D","article-title":"Changes in myocardial and vascular receptors in heart failure","volume":"22","author":"Bristow","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB70","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy","volume":"342","author":"Waagstein","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB71","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure","volume":"90","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.10.022_BIB72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET)","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934303006788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934303006788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:28:32Z","timestamp":1757579312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934303006788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0002934303006788"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2003.10.022","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing the patient with diabetes mellitus and heart failure: issues and considerations","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2003.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Excerpta Medica Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}